Key clinical point: Erenumab demonstrated sustained efficacy along with long-term safety and tolerability in patients with chronic migraine.

Major finding: At week 52, 53.3% of patients in the 70-mg group and 67.3% in the 140-mg group had a ≥50% reduction in monthly migraine days. Reductions in monthly migraine-specific medication use days in the 70-mg and 140-mg groups were −6.2 and −6.7 days, respectively. No new serious or treatment-emergent adverse events were observed in the open-label phase.

Study details: A multicenter, 52-week, open-label extension (n = 470) of a 12-week double-blind study of patients treated with placebo, erenumab 70 mg, or erenumab 140 mg. The initial dose in the open-label phase was 70 mg once monthly, subsequently increased to 140 mg monthly after protocol amendment.

Disclosures: The study was funded by Amgen, Thousand Oaks, CA, USA, and Novartis Pharma AG, Basel, Switzerland. The authors reported ties with 1 or more pharmaceutical companies, including Amgen and Novartis.